SMA

Biotechnology | Disease | FDA | Therapeutics

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

On Mar. 30, 2026, Biogen announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of…

Read More FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Biotechnology | Disease | FDA | Neurology | Therapeutics

FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy

On Feb. 12, 2025, Genentech announced that the U.S. Food and Drug Administration (FDA) has approved a New…

Read More FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy
Biotechnology | Disease | FDA | Therapeutics

FDA approved oral treatment for spinal muscular atrophy

On Aug. 7, 2020, the U.S. Food and Drug Administration (FDA) approved Genentech’s Evrysdi (risdiplam) to treat patients…

Read More FDA approved oral treatment for spinal muscular atrophy
Biotechnology | FDA | Therapeutics

At $2M, priciest ever medicine treats fatal genetic disease

On May 24, 2019, U.S. regulators have approved the most expensive medicine ever, for a rare disorder that destroys…

Read More At $2M, priciest ever medicine treats fatal genetic disease